Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06590454 · ClinicalTrials.gov registry record · Phase 2
REVerse Intestinal Metaplasia in the Stomach (REVISE)
A Phase 2 study of Gastric Intestinal Metaplasia and Gastric Precancer, sponsored by Katherine Garman.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 32
- Enrollment target
- 1
- Study location
NCT06590454: Recruiting Phase 2 study of Gastric Intestinal Metaplasia and Gastric Precancer, sponsored by Katherine Garman.
NCT06590454 is a Phase 2 study of Gastric Intestinal Metaplasia and Gastric Precancer that is actively recruiting participants, run by Katherine Garman. The registered enrollment target is 32 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (76% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06590454, a Phase 2 study of Gastric Intestinal Metaplasia and Gastric Precancer, is actively recruiting participants, sponsored by Katherine Garman.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 32 participants
- Enrollment target
- 1
- Study location
Study Summary
This study is designed to test the use of Pyrvinium vs placebo as a treatment for gastric intestinal metaplasia with features associated with increased risk of cancer. Response will be determined by assessing the extent and quality of the gastric intestinal metaplasia before and after treatment. A secondary aim will be to generate gastric organoids from patient-derived samples to test the effects of pyrvinium in vitro in patient-derived samples, and also to identify new drugs that may help reverse gastric intestinal metaplasia.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Pyrvinium
Study Locations (1)
North Carolina
- Duke Health - Durham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2025-12-15 |
| Est. Completion | 2026-10-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06590454
The ClinicalTrials.gov registry entry for NCT06590454 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (76% lower). The listed sponsor is Katherine Garman, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Gastric Intestinal Metaplasia appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06590454 reports 1 study location spanning 1 distinct geographic area - top geographies include North Carolina.
Frequently Asked Questions
What is clinical trial NCT06590454 about?
NCT06590454 is a clinical study titled "REVerse Intestinal Metaplasia in the Stomach (REVISE)". This study is designed to test the use of Pyrvinium vs placebo as a treatment for gastric intestinal metaplasia with features associated with increased risk of cancer. Response will be determined by assessing the extent and quality of the gastric intestinal metaplasia before and after treatment. A ...
What is the current status of trial NCT06590454?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 32 participants. The study started on 2025-12-15. Estimated completion is 2026-10-01.
What conditions does trial NCT06590454 study?
This clinical trial studies the following conditions: Gastric Intestinal Metaplasia, Gastric Precancer.
What interventions are being tested in trial NCT06590454?
The interventions under investigation include: Placebo (DRUG), Pyrvinium (DRUG).
Who is sponsoring clinical trial NCT06590454?
This trial is sponsored by Katherine Garman, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06590454 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Gastric Intestinal Metaplasia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.